| Literature DB >> 35978037 |
Natalie Ella Miller1, Andrew Steptoe2.
Abstract
Depressive symptoms are associated with increased risk for cardiovascular disease (CVD), and inflammation may contribute to this relationship. Pericardial fat, a highly metabolically active fat depot, is implicated in the pathogenesis of CVD, but its association with depressive symptoms is unclear. This study examined the cross-sectional and longitudinal association between depressive symptoms and pericardial fat over a three-year period. Participants were 543 healthy men and women (mean age = 62.9 years) without history or objective signs of coronary heart disease from the Whitehall II cohort. In men, depressive symptoms were positively associated with pericardial fat at baseline after adjustment for sociodemographics, waist to hip ratio and conventional cardiovascular risk factors. Inflammation, indexed by plasma interleukin 6 concentration, accounted for 17% of this association. Longitudinally, depressive symptoms did not predict pericardial fat three years later in men once baseline levels of pericardial fat were accounted for. No significant associations between depressive symptoms and pericardial fat were found in women. Overall, our findings suggest that greater pericardial fat might be a mechanism by which depressive symptoms are associated with increased risk for CVD in men, and inflammation may also lie on this pathway.Entities:
Mesh:
Year: 2022 PMID: 35978037 PMCID: PMC9385858 DOI: 10.1038/s41598-022-17888-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Participant characteristics at baseline, stratified by sex (observed data).
| Variable | Males | Females | |||
|---|---|---|---|---|---|
| Mean (SD)/ | Mean (SD)/ | ||||
| Age | 294 | 62.04 (5.72) | 249 | 63.89 (5.41) | < 0.001 |
| Grade of employment | 294 | 249 | 0.011 | ||
| Lower | 52 (17.69) | 70 (28.11) | |||
| Intermediate | 126 (42.86) | 86 (34.54) | |||
| Higher | 116 (39.46) | 93 (37.35) | |||
| Smoking status | 294 | 249 | 0.927 | ||
| Non-smoker | 278 (94.56) | 235 (94.38) | |||
| Smoker | 16 (5.44) | 14 (5.62) | |||
| Waist circumference (cm) | 288 | 92.69 (10.49) | 249 | 79.86 (11.69) | < 0.001 |
| Hip circumference (cm) | 288 | 98.46 (6.96) | 249 | 98.47 (8.95) | 0.988 |
| Waist to hip ratio | 288 | 0.94 (0.07) | 249 | 0.81 (0.08) | < 0.001 |
| LDL cholesterol (mmol/L) | 280 | 2.88 (0.81) | 244 | 3.17 (0.89) | < 0.001 |
| HDL cholesterol (mmol/L) | 283 | 1.51 (0.38) | 245 | 1.86 (0.49) | < 0.001 |
| Triglycerides (mmol/L)a | 283 | 1.56 (0.94) | 244 | 1.19 (0.59) | < 0.001 |
| Systolic blood pressure (mmHg) | 288 | 127.92 (13.57) | 240 | 123.94 (15.92) | 0.002 |
| Fasting glucose (mmol/L) | 287 | 5.09 (0.51) | 242 | 5.00 (0.78) | 0.105 |
| Fasting insulin (μIU/mL) | 285 | 7.07 (5.27) | 243 | 6.04 (6.48) | 0.046 |
| HOMA-IRa | 285 | 1.64 (1.49) | 242 | 1.38 (1.98) | 0.086 |
| Interleukin-6 (pg/mL)a | 287 | 1.37 (0.84) | 238 | 1.30 (0.81) | 0.232 |
| Depressive symptoms total score (CES-D) | 294 | 6.32 (6.16) | 248 | 7.05 (6.90) | 0.196 |
| Pericardial fat adjusted for body surface area (cm3/m2) | 285 | 66.45 (24.47) | 188 | 55.44 (18.75) | < 0.001 |
aVariable was log transformed before analysis.
SD standard deviation, HDL high-density lipoprotein, HOMA-IR insulin resistance, LDL low-density lipoprotein.
Regression coefficients showing cross-sectional associations between depressive symptoms and pericardial fat adjusted for body surface area.
| Males ( | Females ( | |||||
|---|---|---|---|---|---|---|
| SE | SE | |||||
| Model 1 | 0.618 (0.136, 1.100) | 0.245 | 0.012* | 0.225 (− 0.216, 0.666) | 0.224 | 0.315 |
| Model 2 | 0.590 (0.160, 1.020) | 0.219 | 0.007** | 0.091 (− 0.341, 0.523) | 0.219 | 0.678 |
| Model 3 | 0.512 (0.099, 0.925) | 0.210 | 0.015* | 0.135 (− 0.315, 0.585) | 0.228 | 0.555 |
| Model 4 | 0.425 (0.027, 0.824) | 0.202 | 0.037* | 0.119 (− 0.334, 0.571) | 0.229 | 0.606 |
SE = robust standard errors to adjust for heteroscedasticity.
*p < 0.05, **p < 0.01, ***p < 0.001.
Model 1 adjusted for age and grade of employment. Model 2 adjusted for age, grade of employment and waist to hip ratio. Model 3 adjusted for age, grade of employment, waist to hip ratio, smoking, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure and HOMA-IR. Model 4 adjusted for age, grade of employment, waist to hip ratio, smoking, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, HOMA-IR and IL-6.
CI confidence interval, HDL high-density lipoprotein, HOMA-IR insulin resistance, LDL low-density lipoprotein, IL-6 interleukin-6.
Longitudinal associations between depressive symptoms and pericardial fat adjusted for body surface area.
| Males ( | Females ( | |||||
|---|---|---|---|---|---|---|
| SE | SE | |||||
| Model 1 | 0.610 (0.111, 1.109) | 0.253 | 0.017* | 0.106 (− 0.337, 0.548) | 0.224 | 0.638 |
| Model 2 | 0.584 (0.129, 1.038) | 0.231 | 0.012* | 0.007 (− 0.399, 0.413) | 0.206 | 0.972 |
| Model 3 | 0.525 (0.102, 0.948) | 0.215 | 0.015* | 0.042 (− 0.373, 0.456) | 0.210 | 0.843 |
| Model 4 | 0.117 (− 0.177, 0.410) | 0.149 | 0.435 | − 0.097 (− 0.267, 0.074) | 0.086 | 0.263 |
| Model 5 | 0.113 (− 0.180, 0.407) | 0.149 | 0.447 | − 0.087 (− 0.268, 0.094) | 0.092 | 0.342 |
SE = robust standard errors to adjust for heteroscedasticity.
*p < 0.05, **p < 0.01, ***p < 0.001.
Model 1 adjusted for age and grade of employment. Model 2 adjusted for age, grade of employment and waist to hip ratio. Model 3 adjusted for age, grade of employment, waist to hip ratio, smoking, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure and HOMA-IR. Model 4 adjusted for age, grade of employment, waist to hip ratio, smoking, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, HOMA-IR and baseline levels of pericardial fat. Model 5 adjusted for age, grade of employment, waist to hip ratio, smoking, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, HOMA-IR, baseline levels of pericardial fat and IL-6.
CI confidence interval, HDL high-density lipoprotein, HOMA-IR insulin resistance, LDL low-density lipoprotein, IL-6 interleukin-6.